Facing cancer takes courage. clonoSEQ helps doctors detect, quantify, and monitor small amounts of cancer known as measurable (or minimal) residual disease (MRD) to inform treatment throughout a …

Detect, quantify, and assess cancer cells that may remain in the body to get the most of of today's advanced therapies. Learn more about clonoSEQ.

Detect subtle changes in disease dynamics by monitoring MRD status. Use clonoSEQ to detect small but significant levels of residual disease.

Covered by Medicare and FDA-cleared, clonoSEQ supports baseline ID assessment to enable subsequent next generation sequencing (NGS)-based MRD tracking. For more info about …

clonoSEQ leverages the power of next-generation DNA sequencing (NGS) and offers an accurate and reliable way to assess how disease burden changes over time in response to treatment or during …

The clonoSEQ Assay B-cell Reagent Set is an in vitro diagnostic that identifies and quantifies rearranged B-cell receptor gene sequences in DNA extracted from blood and bone marrow.

clonoSEQ is a blood or bone marrow test that can detect small traces of cancer that may remain during and after treatment.

Relapse after initial remission is common in ALL. Test regularly with clonoSEQ to measure deep repsonses and detect potential relapse earlier.

clonoSEQ leverages the power of next-generation DNA sequencing (NGS) and offers an accurate and reliable way to assess how disease burden changes over time in response to treatment or during …

The clonoSEQ® Assay is an in vitro diagnostic that uses multiplex polymerase chain reaction (PCR) and next-generation sequencing (NGS) to identify and quantify rearranged IgH (VDJ), IgH (DJ), IgK and …